Ovarian Suppression: Early Menopause and Late Effects
Chiara Molinelli,Flavia Jacobs,Guilherme Nader-Marta,Roberto Borea,Graziana Scavone,Silvia Ottonello,Piero Fregatti,Cynthia Villarreal-Garza,Jyoti Bajpai,Hee Jeong Kim,Silvia Puglisi,Evandro de Azambuja,Matteo Lambertini
DOI: https://doi.org/10.1007/s11864-024-01190-8
2024-03-14
Current Treatment Options in Oncology
Abstract:Around 90% of breast tumours are diagnosed in the early stage, with approximately 70% being hormone receptor-positive. The cornerstone of adjuvant therapy for early-stage hormone receptor-positive breast cancer is endocrine therapy, tailored according to disease stage, biological characteristics of the tumour, patient's comorbidities, preferences and age. In premenopausal patients with hormone receptor-positive breast cancer, ovarian function suppression is a key component of the adjuvant endocrine treatment in combination with an aromatase inhibitor or tamoxifen. Moreover, it can be used during chemotherapy as a standard strategy for ovarian function preservation in all breast cancer subtypes. In the metastatic setting, ovarian function suppression should be used in all premenopausal patients with hormone receptor-positive breast cancer to achieve a post-menopausal status. Despite its efficacy, ovarian function suppression may lead to several side effects that can have a major negative impact on patients' quality of life if not properly managed (e.g. hot flashes, depression, cognitive impairment, osteoporosis, sexual dysfunction, weight gain). A deep knowledge of the side effects of ovarian function suppression is necessary for clinicians. A correct counselling in this regard and proactive management should be considered a fundamental part of survivorship care to improve treatment adherence and patients' quality of life.
oncology